{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Durata+Therapeutics+Inc.%2C+an+affiliate+of+Allergan+plc",
    "query": {
      "sponsor": "Durata Therapeutics Inc., an affiliate of Allergan plc"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 5,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T15:36:12.785Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02127970",
      "title": "Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Abscess",
        "Wound Infection",
        "Surgical Site Infection",
        "Cellulitis"
      ],
      "interventions": [
        {
          "name": "Dalbavancin",
          "type": "DRUG"
        },
        {
          "name": "Dalbavancin-matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Durata Therapeutics Inc., an affiliate of Allergan plc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 698,
      "start_date": "2014-04-18",
      "completion_date": "2015-03-11",
      "has_results": true,
      "last_update_posted_date": "2018-09-28",
      "last_synced_at": "2026-10-10T15:36:12.785Z",
      "location_count": 25,
      "location_summary": "Montgomery, Alabama • Anaheim, California • Long Beach, California + 18 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Modesto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02127970"
    },
    {
      "nct_id": "NCT01946568",
      "title": "A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bacterial Infections."
      ],
      "interventions": [
        {
          "name": "Dalbavancin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Durata Therapeutics Inc., an affiliate of Allergan plc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "3 Months to 11 Years"
      },
      "enrollment_count": 36,
      "start_date": "2013-06",
      "completion_date": "2015-04",
      "has_results": false,
      "last_update_posted_date": "2015-06-23",
      "last_synced_at": "2026-10-10T15:36:12.785Z",
      "location_count": 10,
      "location_summary": "Little Rock, Arkansas • San Diego, California • Hartford, Connecticut + 7 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01946568"
    },
    {
      "nct_id": "NCT01431339",
      "title": "Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Abscess",
        "Wound Infection",
        "Surgical Site Infection",
        "Cellulitis"
      ],
      "interventions": [
        {
          "name": "IV Dalbavancin",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin/Linezolid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Durata Therapeutics Inc., an affiliate of Allergan plc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 739,
      "start_date": "2011-07",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2014-02-12",
      "last_synced_at": "2026-10-10T15:36:12.785Z",
      "location_count": 30,
      "location_summary": "Montgomery, Alabama • Anaheim, California • Buena Park, California + 26 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Buena Park",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01431339"
    },
    {
      "nct_id": "NCT02269644",
      "title": "A P3 Comparator Trial in Community Acquired Bacterial Pneumonia",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Community Acquired Pneumonia"
      ],
      "interventions": [
        {
          "name": "Dalbavancin",
          "type": "DRUG"
        },
        {
          "name": "Linezolid",
          "type": "DRUG"
        },
        {
          "name": "Linezolid Placebo",
          "type": "DRUG"
        },
        {
          "name": "Azithromycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Durata Therapeutics Inc., an affiliate of Allergan plc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 0,
      "start_date": "2015-11",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2016-01-22",
      "last_synced_at": "2026-10-10T15:36:12.785Z",
      "location_count": 1,
      "location_summary": "Butte, Montana",
      "locations": [
        {
          "city": "Butte",
          "state": "Montana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02269644"
    },
    {
      "nct_id": "NCT01339091",
      "title": "Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Abscess",
        "Wound Infection",
        "Surgical Site Infection",
        "Cellulitis"
      ],
      "interventions": [
        {
          "name": "Dalbavancin",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin / Linezolid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Durata Therapeutics Inc., an affiliate of Allergan plc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 573,
      "start_date": "2011-03",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2014-01-31",
      "last_synced_at": "2026-10-10T15:36:12.785Z",
      "location_count": 55,
      "location_summary": "Anaheim, California • Azusa, California • Bellflower, California + 50 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Buena Park",
          "state": "California"
        },
        {
          "city": "Carmel",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01339091"
    }
  ]
}